- Home
- ROIV vs BLSH Comparison
ROIV vs BLSH Comparison
Compare ROIV & BLSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- BLSH
- Stock Information
- Founded
- ROIV 2014
- BLSH 2020
- Country
- ROIV United Kingdom
- BLSH Cayman Islands
- Employees
- ROIV N/A
- BLSH N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- BLSH Finance: Consumer Services
- Sector
- ROIV Health Care
- BLSH Finance
- Exchange
- ROIV Nasdaq
- BLSH Nasdaq
- Market Cap
- ROIV 8.6B
- BLSH 10.2B
- IPO Year
- ROIV N/A
- BLSH 2025
- Fundamental
- Price
- ROIV $12.92
- BLSH $52.39
- Analyst Decision
- ROIV Strong Buy
- BLSH Hold
- Analyst Count
- ROIV 4
- BLSH 1
- Target Price
- ROIV $15.50
- BLSH $45.00
- AVG Volume (30 Days)
- ROIV 5.2M
- BLSH 10.0M
- Earning Date
- ROIV 08-11-2025
- BLSH 01-01-0001
- Dividend Yield
- ROIV N/A
- BLSH N/A
- EPS Growth
- ROIV N/A
- BLSH N/A
- EPS
- ROIV N/A
- BLSH N/A
- Revenue
- ROIV $23,233,000.00
- BLSH $250,105,767,000.00
- Revenue This Year
- ROIV N/A
- BLSH N/A
- Revenue Next Year
- ROIV $281.14
- BLSH N/A
- P/E Ratio
- ROIV N/A
- BLSH N/A
- Revenue Growth
- ROIV N/A
- BLSH 18824.97
- 52 Week Low
- ROIV $8.73
- BLSH $47.89
- 52 Week High
- ROIV $13.08
- BLSH $118.00
- Technical
- Relative Strength Index (RSI)
- ROIV 73.31
- BLSH N/A
- Support Level
- ROIV $11.85
- BLSH N/A
- Resistance Level
- ROIV $13.08
- BLSH N/A
- Average True Range (ATR)
- ROIV 0.31
- BLSH 0.00
- MACD
- ROIV 0.10
- BLSH 0.00
- Stochastic Oscillator
- ROIV 89.61
- BLSH 0.00
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.